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ABSTRACT 
Inhibition of Janus kinases in Crohn’s disease (CD) patients has shown 
conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor showed efficacy in 
ulcerative colitis (UC) and has been approved for the treatment of patients with 
moderate to severe UC. In contrast, studies in patients suffering from CD were 
disappointing and the primary endpoint of clinical remission could not be met in the 
respective phase II induction and maintenance trials. Subsequently, the clinical 
development of tofacitinib was discontinued in CD. In contrast, efficacy of filgotinib, a 
selective JAK1 inhibitor, in CD patients was demonstrated in the randomized, 
double-blinded, placebo-controlled phase II FITZROY study. Upadacitinib also 
showed promising results in a phase II trial in moderate to severe CD. Subsequently 
phase III programs in CD have been initiated for both substances, which are still 
ongoing. Several newer molecules of this class of orally administrated 
immunosuppressants are tested in clinical programs. The concern of side effects of 
systemic JAK inhibition is addressed by either exclusively intestinal action or higher 
selectivity (Tyk2 inhibitors). In general, JAK inhibitors constitute a new promising 
class of drugs for the treatment of CD. 
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INTRODUCTION 
 
Many treatment strategies for patients with Crohn’s disease (CD) and ulcerative 
colitis (UC) are similar despite the fact that both disease have different 
characteristics and most likely also different pathophysiology. Steroids, thiopurines 
(for maintenance of remission), anti-TNF antibodies, anti-aplha4beta7-integrin 
antibodies and anti-IL-23 antibodies have shown clinical efficacy in both subtypes of 
inflammatory bowel diseases (IBD) 1. However, a significant number of patients still 
is insufficiently treated, surgery is frequent in CD and 10-15% of patients with UC still 
undergo colectomy. 
Subsequently, Janus kinase (JAK) inhibitors were considered for clinical trials 
in both CD and UC and clinical trials programs for different compounds from this 
substance class have been established for both IBD entities 2-4. Tofacitinib, a pan-
JAK inhibitor, in the meantime has been approved for the treatment of patients with 
moderate to severe UC 5-11. Reports on the clinical testing of three JAK inhibitors in 
patients with moderate-to-severe CD have been published: tofacitinib (pan-JAK 
inhibitor) 10, filgotinib (JAK1 inhibitor) 12 and upadacitinib (JAK1 inhibitor) 12.  
Why did the inhibition of Janus kinases appear to be a promising new treatment 
strategy in IBD? Janus kinases phosphorylate activated cytokine receptors and are 
necessary for their signal transduction 13,14. They are located intracellularly and 
belong to the large family of tyrosine kinases, enzymes that bind a phosphate group 
to the amino acid tyrosine (tyrosine phosphorylation) 2,15. Subsequently, these 
molecules are involved in the transduction of cytokine-transmitted signals from the 
cell surface to the cell nucleus to modify gene expression 2,15. Cytokines bind to their 
specific receptors on the surface of the target cells (e.g. lymphocytes or 
macrophages). After binding of the cytokines such as interleukin 6 (IL-6) or IL-2 and 
IL12 and IL-23 to their receptors the conformation of the receptor is changed and 
JAKs are activated to phosphorylate the receptor. This phosphorylation of the 
respective receptors by the tyrosine kinases of the JAK family allows members of the 
“signal transducer and activator of transcription” (STAT) protein family to bind to the 
receptor. They also become phosphorylated and subsequently form dimers, which 
then dissociate from the receptor and move into the nucleus where they change the 
transcription of genes 2,15.  
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Many cytokine receptors rely on the JAK family proteins to transmit the signals 
after binding of a specific cytokine molecule. In contrast, this is not the case for 
example for TNF receptors: TNF receptors require other proteins that get bound to 
them to initiate intracellular signal transduction such as “Tumor necrosis factor 
receptor type 1-associated DEATH domain protein” (TRADD), “TNF receptor 
associated factors” (TRAFs), “Receptor-interacting protein (RIP) kinases” and “Fas-
associated protein with death domain” (FADD) 16-18. Nevertheless, there is a 
connection between TNF and the JAK/STAT pathways: After binding of TNF to its 
receptor STAT proteins (that are involved in JAK induced signal transduction) are 
up-regulated. TNF action thereby can amplify the signal transduction of JAK 
dependent receptors indicating that these pathways are not completely independent 
but influence each other. 
Receptors that use JAK family members, however, are not only mediating pro-
inflammatory signals. Among the cell surface receptors that depend on JAK signaling 
are also the erythropoietin receptor 19 and “Granulocyte-macrophage colony-
stimulating factor” (GM-CSF) 20-22 as well as “Granulocyte colony-stimulating factor” 
(G-CSF) 23. This explains why JAK inhibitors can be applied in myeloproliferative 
disorders. It also explains some side effects seen with certain compounds such as 
anemia (blockade of erythropoietin signaling). 
Four different proteins belong to the JAK family of tyrosine kinases: JAK1, 
JAK2, JAK3 and “tyrosine-protein kinase 2” (TYK2) 2. In different combinations, 
usually two of these protein family members are associated with a certain receptor 
type 2.  
JAK inhibitors are under development for a variety of disease besides IBD, 
such as the treatment of rheumatoid arthritis, psoriasis, polycythemia vera, alopecia, 
thrombocythemia, myelofibrosis and vitiligo. Different compounds have different 
specificities for different JAKs or TYK. There is an ongoing discussion which profile 
of JAK inhibition would be optimal for which specific disease. The first approved JAK 
inhibitor (by FDA in 2011) was ruxolitinib (trade names Jakafi/Jakavi) against 
JAK1/JAK2 for psoriasis, myelofibrosis and rheumatoid arthritis 24-26. Tofacitinib 
(trade names Xeljanz/Jakvinus), a pan-JAK inhibitor, was first approved in November 
2012 initially in rheumatoid arthritis in patients who had an inadequate response or 
intolerance to methotrexate 27-31. Peficitinib (ASP015K, JNJ-54781532; trade name 
Smyraf) was approved for the treatment of rheumatoid arthritis in Japan in 2019 32. 
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Fedratinib (SAR302503; trade name Inrebic) was approved the FDA in August 2019 
for treatment of myelofibrosis and essential thrombocythemia 33. Upadacitinib (trade 
name Rinvoq; ABT-494) targeting mainly JAK1 also was approved by the FDA for 
the treatment of rheumatoid arthritis in August 2019 34-38.  
Filgotinib (G-146034, GLPG-0634) also is relatively specific for JAK1. In spring 
2019, Gilead and Galapagos announced that the Phase 3 FINCH 1 and FINCH 3 
trials in rheumatoid arthritis patients met the primary and key secondary endpoints 39. 
Earlier, in 2018, it was reported that the TORTUGA Phase 2 trial of filgotinib in 
ankylosing spondylitis met the primary endpoint 40 and well as the EQUATOR Phase 
2 trial of filgotinib in psoriatic arthritis 41,42.  
Further JAK inhibitors in clinical development are Cerdulatinib (PRT062070) for 
hematological malignancies 43,44, Gandotinib (LY-2784544) for myeloproliferative 
neoplasms 45, Lestaurtinib (CEP-701) for acute myeloid leukemia 46,47, Momelotinib 
(GS-0387, CYT-387) for myeloproliferative disorders 48,49, Pacritinib (SB1518) for 
relapsed lymphoma and advanced myeloid malignancies 50,51 and PF-04965842 for 
atopic dermatitis and moderate to severe psoriasis 52.  
 
 
METHODS 
For this review on the efficacy of JAK inhibitors in CD, PubMed, Embase and 
CENTRAL were systematically searched to October 1, 2019. Randomised placebo‐
controlled trials (RCTs) of JAK inhibitors in adult patients with CD were eligible. 
Additional information was retrieved from the Trials.gov database. MEDLINE was 
searched via PubMed, EMBASE via Ovid and The Cochrane Central Register of 
Controlled Trials (CENTRAL). 
Furthermore, the reference lists of included studies and systematic reviews from the 
last five years on JAK therapy for management of inflammatory bowel disease were 
searched for relevant studies.  
The following search strategy was performed in the respective databases: 
("Crohn*[TIAB] OR IBD [TIAB] OR Inflammatory bowel disease*[TIAB] AND JAK 
[MeSH] OR janus kinase inhibitor[TIAB]) AND (randomized controlled trial 
[Publication Type] OR controlled clinical trial [Publication Type] OR randomized  
[TIAB] OR placebo [TIAB] OR drug therapy [Subheading] OR randomly [TIAB] OR 
trial [TIAB] OR groups [TIAB]). Non-English literature was excluded.  
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w 
LACK OF EFFICACY OF TOFACITINIB IN CROHN’S DISEASE 
As mentioned above Tofacitinib (Pfizer Inc., New York, United States) has shown 
promising results for the treatment of UC and has been approved by FDA and EMA 
as well as other regulatory agencies (e.g. SwissMedic) 5,7,53-56. Tofacitinib is a rather 
broad JAK inhibitor that besides a main activity for JAK1 and JAK3 also inhibits 
tyrosine kinases outside the JAK family 2,55. Therefore, it has always been a matter 
of discussion whether its action can solely be attributed to JAK inhibition 2. 
Tofacitinib has a functional half-life of ~3 h making multiple dosing more promising 
than single dosing 57-59. Hepatic metabolism (70%) is more important than renal 
clearance (30%) for the excretion of the drug 57-59. This explains why both liver 
disease and renal insufficiency have to be taken into account when oral dosing is 
decided.  
 
Tocatinib was tested in CD patients initially in a clinical phase IIa induction of 
remission design (NCT00615199) 60. The results presented by Sandborn and 
coworkers of this 4-week induction study with moderate-to-severe CD were reported 
in 2014 60. 139 CD patients were randomized to either placebo, tofacitinib 1 mg, 5 
mg, or 15 mg twice daily (BID). 48 centers in 12 countries contributed to this 
placebo-controlled, randomized multicenter trial 60. The primary endpoint in this trial 
was not clinical remission but clinical response at week 4 (defined as a decrease 
from baseline in the Crohn's Disease Activity Index (CDAI) score of > 70 points 
[CR70]). A secondary end point was clinical remission (CDAI <150) at week 4. In 
contrast to the findings for UC patients disappointingly no differences in clinical 
response or remission between the placebo group and the treatment groups could 
be observed. A clinical response was seen in 47% of placebo treated patients, 36% 
of patients receiving 1 mg tofacitinib BID, 58% in the 5mg BID group and 46% in the 
15 mg group 60. Clinical remission was reported in 21% of placebo treated patients 
and in 31%, 24% and 14% of the 1-, 5-, and 15-mg groups of tofacitinib treated 
patients 60. In the 15-mg dose group reduced levels of CRP and fecal calprotectin as 
compared to baseline were reported. Placebo response and remission rates in this 
trial were greater than expected and higher as in comparable studies on anti-TNF 
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antibodies. The study was criticized because of the short time for induction therapy 
of only four weeks. This four week end-point was initially chosen to reduce placebo 
response rates group 60. In addition, the selected patients had a relatively mild 
disease course: only 21% of placebo patients previously had received thioguanines 
and only 2% previously had failed anti-TNF therapy 60. Furthermore, only 56% of 
patients had increased fecal calprotectin concentrations (>250 microg/g feces).  
 
Subsequently, tofacitinib for the induction and maintenance of remission and clinical 
response in patients with CD was further investigated in two placebo-controlled, 
randomized, multicenter IIb trials (NCT013932626 and NCT01393899) reported by 
Panes et al. in 2017 61. Patients were enrolled into two sequential and integrated 
phase IIb, randomised, double-blind, placebo-controlled, parallel-group, dose-
ranging, multicentre trials for induction (induction study) and maintenance 
(maintenance study) of remission 61. The studies were conducted at 80 sites in 18 
countries. Adult patients with moderate-to-severe CD (CDAI between 220 and 450) 
were included. Endoscopic activity had to be confirmed, however, not by central 
reading. Patients with an inadequate response or intolerance to steroids, thiopurines, 
methotrexate, or anti-TNF antibodies were eligible. The study design intended a 
3:2:2:4 randomization (placebo, 5, 10, or 15mg tofacitinib BID). Treatment duration in 
the induction-trial was eight weeks. The 15 mg BID treatment group was stopped 
during the trial and patients finally were randomized 1:1:1 (placebo, 5 or 10mg 
tofacitinib BID) 61. If patients had a significant reduction of disease activity (decrease 
of CDAI of > 100 points) or achieved a clinical remission (as usual defined as CDAI 
<150) at week 8 they could be re-randomized 1:1:1 to receive either placebo or 
tofacitinib 5 or 10mg BID for another 26 weeks (maintenance phase). Steroid 
tapering during the maintenance study was mandatory with a reduction of 
corticosteroid doses of 5mg prednisolone-equivalent weekly until 20 mg/day, and 
then by 2.5 mg/week until 10 mg/day.  
 
In the induction study the primary endpoint was clinical remission (as mentioned, 
CDAI <150 at week 8). Secondary endpoints in the induction study were clinical 
response with a decrease of the CDAI of either 70 points (CR70) or 100 points 
(CR100) as compared to baseline CDAI 61. 280 CD patients were randomized in the 
induction study (92 placebo treated and 86 either 5mg or 10 mg tofacitinib treated). 
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There was a high rate of patients pre-exposed to anti-TNF antibodies: 76.9% in the 
placebo arm and 77.9% treated with tofacitinib 61.  
 
At the end of the treatment phase at week 8 no significant differences between the 
placebo group and the treatment groups could be observed (figure 1). Clinical 
remission was reported for 36.7% placebo treated patients, 43.5% of patients treated 
with 5 mg tofacitinib BID and 43.0% of patients for 10 mg tofacitinib BID 61. The high 
rate of patients achieving remission in the placebo arm again was surprising. With 
respect to secondary endpoint a significantly higher rate of the CR100 (reduction of 
100 points in CDAI) was seen with 5 mg tofacitinib BID as compared to placebo 
(70.6% vs. 54.4%, p < 0.05). Similar the reduction of 70 points in CDAI was 
significantly higher in the 5 mg tofacitinib group as compared to placebo treated CD 
patients (76.5% vs. 62.2%, p < 0.05). However, again the high placebo response 
rates were surprising and unexpected.  
 
Further, Panes et al. performed a post-hoc an lysis: As patient reported outcomes 
were regarded to be increasingly important by the regulators the investigators 
analyzed the “patient reported outcome” (PRO) remission: Two PRO scores were 
evaluated. The PRO2 (calculated as the sum of stool frequency and abdominal pain 
scores) for which remission is <75, and the PRO3 (calculated as the sum of stool 
frequency, abdominal pain and general well-being scores) for which remission is 
defined <80 points 61. For the PROs Panes et al. found differences between placebo 
and treatment groups, PRO2: 40.0% versus 58.8%, p < 0.05 and PRO3 24.4 versus 
38.8%, p < 0.05). Furthermore, patients treated with tofacitinib had greater mean 
decreases in CRP over the course of the study as compared to placebo (p < 0.001) 
61. In contrast, there were surprisingly no significant differences for fecal calprotectin 
between the groups. 
 
For the maintenance study (randomization at week 8 of the inductions study) the 
primary endpoint was defined as clinical remission (CDAI < 150) or clinical response 
(CR100) at week 26 61. Secondary endpoints were change in CRP and fecal 
calprotectin. 180 patients could be re-randomized for this maintenance study. 59 
patients received placebo, 60 patients were in the 5 mg tofacitinib BID group, and 61 
patients were randomized to the 10 mg tofacitinib BID group. Similar to the induction 
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study the primary endpoint of the maintenance trial was not achieved (figure 2) 61. 
There was no significant difference for the patients that were in clinical remission at 
week 26 and no difference for clinical response (CR100). For the secondary 
endpoints, significantly lower CRP and fecal calprotectin was observed in the 10 mg 
tofacitinib group as compared to placebo.   
 
Whereas the primary endpoints of both studies could not be met, a modest effect of 
tofacitinib was seen for the secondary endpoints of CR70 and CR100 at week 8 61. 
Again the relatively high placebo rates raised doubts regarding the study design. The 
lack of a requirement for central reading was highlighted, however, it remains 
questionable whether this had such a high influence. An important aspect certainly 
is, that there was no protocol deﬁned threshold for an objective marker of disease 
activity e.g. for CRP or fecal calprotectin levels at baseline.  
 
The further development of tofacitinib in CD was stopped after these trials. 
 
FILGOTINIB HAS DEMONSTRATED EFFICACY IN PHASE II IN CROHN’S 
DISEASE 
 
Filgotinib (GLPG0634, GS-6034, Galapagos) has a 28-fold selectivity for JAK1 over 
JAK2 and is subsequently regarded as a JAK1 targeted JAK inhibitor. Filgotinib has 
a longer half life of ~6 h for the parent compound and ~23 h for the active metabolite 
as compared to tofacitinib 62. This allows a once daily dosing. 
 
The efficacy of filgotinib for the induction of remission in moderate to severe CD 
patients was studied in the randomized, placebo-controlled, multicenter phase II 
FITZROY study 12. The inclusion criteria were targeted on adult CD patients with a 
CDAI between 220 and 450. 52 centers in nine European countries contributed. In 
contrast to the tofacitinib studies the FITZROY design included a central endoscopy 
reading. Patients could be included if the central reader agreed that there was an 
ulceration score of >1 in at least one ileocolonic segment and total SES-CD > 7. 
Eligible patients were randomized 1:3 to placebo or filgotinib 200mg once daily 12. 
Stratification was performed according to anti-TNF antibody exposure, baseline 
corticosteroid use and baseline CRP. The initial treatment period was 10 weeks 12. 
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After 10 weeks, patients not responding to placebo were switched to filgotinib 100mg 
daily for 10 weeks. Responders from the filgotinib group were re-randomized 1:2:2 to 
receive either placebo or filgotinib 100mg daily or 200mg daily. The complicated 
study design was completed by an arm for non-responders to filgotinib during the 
initial 10 weeks. They were randomized 1:3 to receive ether placebo or 200mg 
filgotinib daily.  
 
The primary endpoint of the FITZROY study was clinical remission (CDAI < 150) at 
week 10 12. Secondary endpoints were clinical response (as measured by CDAI and 
PRO2), endoscopic response (SES-CD reduction > 50%), endoscopic remission 
(SES-CD < 4 and ulcerated surface subscore < 1 in all segments), mucosal healing 
(SES-CD = 0), deep remission (CDAI<150 and SES-CD< 4 and ulcerated surface 
subscore < 1 in all segments) as well as changes in CRP and fecal calprotectin 12. 
Endoscopic readouts were evaluated by central reading. In the FITZROY study 174 
patients were randomized. Of them 44 patients received placebo and 130 patients 
received 200mg filgotinib daily. 
 
The primary endpoint was reached in the FITZROY study (figure 1). Clinical 
remission was found in 23% of CD patients treated with placebo as compared to 
47% of patients that received 200 mg filgotinib daily (p=0.0077) in the intention-to-
treat population (Δ 24 %) 12 (figure 1). The difference was higher in anti-TNF naïve 
patients (13% vs 60%) 12. With respect to the secondary endpoints a significant 
difference was seen for CR100 (41% vs 59%, p < 0.05) and PRO2 (30% vs. 50% (P 
< 0.03) 12. No significant difference between placebo and filgotinib 200 mg was 
observed for the following secondary endpoints: SES-CD 50% response (14% vs. 
25, p = 0.16), endoscopic remission (7% vs. 14%,  p = 0.31), mucosal healing (2% 
vs 4%, p = 0.82), and deep remission (2% vs 8%, p = 0.31). Especially the low rates 
for endoscopic remission and mucosal healing were somewhat disappointing. For 
the second 10 weeks study period 50% (200 mg) and 71% (100 mg) of initial 
filgotinib responders randomized were in clinical remission at week 20. However, this 
second study part was not powered for statistical analysis (figure 2). 
 
Despite the relatively disappointing rates for endoscopic endpoints and mucosal 
healing (only 4% of patients achieved mucosal healing) the overall positive data 
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stimulated a large phase III induction and maintenance trial evaluating filgotinib in 
moderate-to-severe CD (Diversity1, NCT02914561). Furthermore, a phase II trial 
evaluating the efficacy of filgotinib in fistulizing Crohn’s disease has been initiated 
(Divergence2, NCT03077412). In addition, a phase II trial evaluating the efficacy of 
filgotinib for small bowel CD has been started (NCT03046056). 
 
 
UPADACITINIB DOES NOT REACH ITS PRIMARY ENDPOINTS IN PHASE II IN 
CROHN’S DISEASE BUT MEETS SOME SECONDARY ENDPOINTS 
 
Upadacitinib (ABT-494, AbbVie) similar to Filgotinib is an oral JAK1 selective 
inhibitor with an even higher (74-fold) selectivity for JAK1 over JAK2 63. Upadacitinib 
has a half-life of ~4 h, which is shorter than filgotinib 63. Similar to tofacitinib 
upadacitinib is eliminated 80% via hepatic metabolization [CYP3A4 & CYP2D6] and 
20% by urinary excretion (20%). Subsequently hepatic and renal functions need to 
be considered for dosing. 
 
The efficacy of upadacitinib for the induction and maintenance of remission in 
moderate-to-severe CD patients was studies in a randomized, placebo-controlled 
multicenter phase II trial (CELEST) which so far is only published in abstract form 64-
67.  
 
The study design included a 16-week induction phase and a 36-week blinded 
extension phase. Similar to the above mentioned trials patients were eligible when 
they had moderate to severe CD with a CDAI between 220 and 450. Again, the 
endoscopic activity was evaluated to only include truly inflamed and active CD 
patients (SES-CD > 6 or > 4 for isolated ileal disease). Patients were randomized to 
receive either placebo or 3, 6, 12, 24mg BID or 24 mg once upadacitinib 66-68. The 
number of patients that had previously received anti-TNF therapy was the highest of 
all trials reported here: 96% of patients in CELEST were anti-TNF experienced 66-68. 
The co-primary endpoints were clinical remission and endoscopic remission (SES-
CD < 4 and >2-point reduction from baseline with no subscore >1). Secondary 
endpoints were modified clinical remission (stool frequency score < 2.8 and 
abdominal pain score < 1.0) clinical response (defined by a > 30% reduction scores) 
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and endoscopic response (defined by > 25% reduction in baseline SES-CD). 220 
patients were randomized in the CELEST trial of whom 37 received placebo, 39 
received 3mg upadacitinib BID, 37 received 6mg upadacitinib BID, 36 received 12 
mg upadacitinib BID, 36 received 24 mg upadacitinib BID, and 35 received 24 mg 
upadacitinib once daily 66-68.  
 
At week 16 clinical remission was not significantly different for the upadacitinib 
groups as compared to placebo (figure 1). The highest difference was seen for 6 mg 
upadacitinib BID versus placebo for PRO-defined clinical remission (11%  vs 27%, P 
< 0.10). However, no clear dose response could be observed (figure 1). In subgroup 
analyses for patients receiving corticosteroids at baseline, clinical remission was 
significantly more frequent in patients treated with upadacitinib 24 mg BID (0% vs 
33.3%, p < 0.05) 65,68,69. For the secondary endpoint of endoscopic remission a dose 
response could be found 65,68,69. Whereas no patients treated with placebo achieved 
endoscopic remission 14% of CD patients treated with upadacitinib 24 mg daily and 
22% of CD patients treated with upadacitinib 24 mg BID were in endoscopic 
remission at week 16 (p < 0.05 and p < 0.01, respectively). Patients that received 
either 6mg upadacitinib BID, 12 mg upadacitinib BID, 24 mg upadacitinib BID, or 24 
mg upadacitinib daily were more likely to achieve > 25% and >50% reductions in 
SES-CD as compared to placebo (p < 0.05 for all comparisons) 65,66,69-72. 
 
After the 16-week induction patients were randomized 1:1:1 to receive either 3mg 
upadacitinib BID, 12 mg upadacitinib BID, or 24 mg upadacitinib once daily for 36 
weeks. The protocol was amended to drop the 24 mg once daily dose and instead a 
6 mg upadacitinib BID treatment arm was added. 180 patients were re-randomized. 
A certain dose dependency was observed: In patients that had achieved clinical 
response by week 16, clinical remission was observed in 25% (3mg BID), 28.6% 
(6mg BID), 41.4% (12 mg BID), and 31.6% (24 mg once daily) of patients receiving 
upadacitinib (figure 2). In patients that had achieved clinical AND endoscopic 
response at week 16, endoscopic remission was observed in 25% (3mg BID), 25% 
(6mg BID), 37.5% (12 mg BID), and 10% (24 mg once daily) of patients receiving 
upadacitinib 64 
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Based on the findings of the CELEST trial two large phase III trials enrolling patients 
failing either biologic (NCT03345836) or conventional non-biologic (NCT03345849) 
therapies have been initiated. 
 
 
NEW JAK RELATED MOLECULES IN DEVEOPMENT IN CD 
 
Preliminary data suggest that besides the “classical” JAKs TYK2 may be a 
therapeutic target in CD. No TYK2-selective so far is approved by the agencies. 
TKY2 is involved in IL-12, IL-13 and IFN signaling. The relative narrow range of 
cytokines dependent on TYK2 may reduce side effects of inhibition 73. 
 
Therefore, BMS-986165 (Bristol-Myers Squibb) is now studied in IBD clinical trials. 
BMS-986165 selectively inhibits TYK2 74,75. It binds exclusively to the active catalytic 
site of TYK2 which irreversibly inhibits TYK2 activation 74.  A phase II placebo-
controlled, randomized, multicenter, multidosing interventional study (LATTICE) has 
been initiated to evaluate the safety and efficacy of BMS-986165 for the induction 
and maintenance of remission in patients with moderate-to-severe CD.  
 
With respect to optimization of efficacy PF-06700841 and PF-06651600 (Pfizer) are 
currently studied in IBD. JAK2 forms a homodimer important for erythropoietin 
signaling. To avoid JAK2 inhibition mediated side effects, dual JAK1/TYK2 inhibition 
without influence on JAK2 signaling could be interesting. PF-06700841 is a new 
selective JAK inhibitor also mainly targeting TYK2 but also JAK1 76,77. 
 
In contrast, PF-06651600 is a selective JAK3 inhibitor 78,79. In vitro, PF-06651600 
was shown to inhibit Th1 and Th17 cell differentiation. PF-06700841 and PF-
06651600, are currently under study in phase II in patients with moderate-to-severe 
CD. 
 
Another approach to avoid side effects of JAK inhibitors is a non-systemic but local 
application. TD-1473 (Theravance Biopharma) is pan-JAK inhibitor (inhibiting JAK1, 
JAK2, JAK3 and TYK2) with high affinity. However, it is not absorbed and thus 
distributes only in the intestinal tract, reducing systemic exposure 80,81. It is 
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subsequently regarded to have a gut selective action. In a phase I trial in patients 
with UC the safety, tolerability and pharmacodynamics of TD-1473 were evaluated 
82,83. TD-1473 was well tolerated over 4 weeks, without serious or opportunistic 
infections. Low plasma levels and higher colonic tissue concentrations confirmed gut 
selectivity. Phase II and phase III trials have been initiated to study the efficacy of 
TD-1473 for the induction and maintenance of remission in patients with moderate to 
severe CD.  
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SAFETY PROFILE OF JAK INHIBITION IN CD PATIENTS 
 
JAK inhibitors have shown a pattern of safety signals in different patient groups. An 
about 4-fold increased risk for herpes zoster was reported for tofacitinib in patients 
with rheumatoid arthritis or UC. Furthermore, FDA and EMEA warning with respect 
to thromboembolic complications were released for tofacitinib in 2019. Patients with 
thromboembolic risk factors such as hormonal contraceptives should not receive the 
10 mg BID dosage according to the EMEA warning.  
 
In the CD induction studies with tofacitinib adverse events (AEs) were reported for 
60.4%, 58.1%, and 60.5% of patients receiving placebo, or tofacitinib 5mg and 10 
mg BID. In the maintenance study with tofacitinib, AEs were reported in 74.6%, 
83.3%, and 78.7% of patients, receiving placebo, or tofacitinib 5mg and 10 mg BID 
60,61. Serious adverse events (SAEs) were more frequently reported in the 
maintenance study mainly in patients receiving 10 mg tofacitinib BID (11.6% in 
induction, 13.1% in maintenance) as compared to 5 mg BID (3.5% in induction, 
10.0% in maintenance) or placebo (3.3% in induction, 11.9% in maintenance) 61. In 
the maintenance study, three patients in the tofacitinib 5mg BID group reported 
serious infections and two patients in the tofacitinib 10 mg BID group. No cases of 
opportunistic infections (OI) were reported. Similar to other studies two cases of 
herpes zoster were reported the tofacitinib 10 mg BID group. No thromboembolic 
complications were reported in the CD trials.  
 
For the FITZROY study in the pooled safety analysis of both parts AEs were not 
significantly different between the placebo group and the filgotinib groups (67% 
versus 75%) 12. SAEs were also not statistically more frequent in the filgotinib groups 
albeit there was a numerical difference (4% for placebo, 9% for filgotinib). This is 
relevant, as serious infections were only reported in filgotinib treated patients (4/152) 
12. Again, there was a signal for herpes zoster, making a group effect for JAK 
inhibitor likely.  
 
In the CELEST study for upadacitinib the occurrence of AEs was not significantly 
different between the placebo group (73%) and the upadacitinib arms (82%) 67,68. In 
contrast, SAEs occurred in 5% of patients in the placebo group whereas 15% of 
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patients in the upadacitinib arms had SAEs 67,68. Serious infections occurred in eight 
patients on upadacitinib. Among them were four cases of sepsis. Furthermore, two 
patients on upadacitinib had a myocardial infarction and two patients suffered from 
small bowel perforations 67,68. 
 
As mentioned  EMA recently recommended that tofacitinib 10mg BID should not be 
given to patients with thromboembolic risk factors such as current use of oral 
contraceptive or hormonal therapy, decompensated heart disease, history of 
previous thromboembolic events, hereditary coagulopathy, cancer and patients with 
recent major surgical interventions 84. Pulmonary embolisms also occurred in the UC 
developments program for tofacitinib 84.  
 
DISCUSSION 
 
JAK inhibitors represent an interesting class of molecules. A number of compounds 
have been approved for a variety of hematological and auto-immune diseases. The 
development of JAK inhibitors in the field of IBD has also shown progress over the 
last years.  
 
Whereas data in UC are promising and have led to the approval of tofacitinib, 
treatment results in CD are in general less impressive so far. The study design of the 
tofacitinib studies has been criticized and the high placebo rate found in the 
tofacitinib trials in CD patients certainly raises concerns. However, endoscopic 
endpoints in the FITZROY or CELEST studies also show no groundbreaking effect 
albeit treatment periods in the trials have been short (8-10 weeks). 
 
Nevertheless, JAK inhibitors are an attractive therapeutic option also in CD patients 
as their oral bioavailability is high. The safety profile certainly needs to be 
investigated in more details. The occurrence of thromboembolic complications, 
herpes zoster and serious infections raises concerns. Risk/benefit analyses should 
be performed for this class of compounds in CD. An appealing approach certainly 
are more specific (e.g. TYK2 inhibition) or gut selective compounds that are under 
development. 
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Figure 1: Induction of clinical remission 
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Figure 2: Maintenance  of  remission 
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